Kornimate/medical-research-clean huggingface dataset:
89zr-dfo-regn3767 in pet scans in people with diffuse large b cell lymphoma (dlbcl)

Conditions: Large B-cell Lymphoma; DLBCL

Summary: the main purposes of this study include: looking at the way the body absorbs, distributes, and gets rid of 89zr-dfo-regn3767 finding the best dose amount of 89zr-dfo-regn3767 finding the best time for pet scanning after injection of 89zr-dfo-regn3767


Eligibility criteria:
inclusion criteria: a patient must be eligible for dlbcl expansion cohort 9 in study 17-421 and, in addition, meet the following criteria to be eligible for inclusion in the study: * measurable disease by lugano criteria, with at least one lesion outside of the liver * patients must have egfr \>50 ml/min/1.73m2. exclusion criteria: a patient must be eligible for dlbcl expansion cohort 9 in study 17-421 and, in addition, a patient who meets any of the following criteria will be excluded from the study: * patients who have permanently discontinued anti-cancer immune modulating therapies due to drug-related toxicity. * has not yet recovered (i.e. ≤ grade 1 or baseline) from any acute toxicities from prior anticancer therapy except for laboratory changes as described in inclusion criteria in study 17-421, except as noted. note: patients with chronic or stable toxicity following approved therapy, such as mild persistent neuropathy, are allowed. * has received radiation therapy within 14 days of first administration of study drug or has not recovered (i.e. ≤ grade 1 or baseline) from adverse events, except for laboratory changes as described in inclusion criteria, except as noted. note: patients with chronic or stable toxicity, such as mild persistent neuropathy, are allowed. * women who are pregnant, breastfeeding \*postmenopausal women must be amenorrhoeic for at least 12 months in order not to be considered of childbearing potential. pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation. pregnancy testing and screening will be performed per msk and department of radiology standard pregnancy screening guidelines.

Keywords: large b-cell lymphoma dlbcl memorial sloan kettering cancer center 19-479 89zr-dfo-regn3767 anti lag-3 antibody
a comparative study of the outcomes of 2 surgical procedures for safe type of chronic otitis media

Conditions: Chronic Otitis Media; Tubotympanic Disease

Summary: mastoidotympanoplasty is a recognised surgery that is performed for chronic otitis media. but whether mastoidectomy in addition to tympanoplasty is really necessary in each and every case of quiescent chronic otitis media still remains controversial. hence this study has been undertaken to study the differences in the outcomes of the 2 surgical procedures performed for chronic otitis media in a randomized control design.

design: single blinded randomized control study. setting: tertiary referral medical college hospital. sample size: 60. no of groups: 2 \[30 cases in each group\]. group 1: patients undergoing mastoidotympanoplasty. group 2: patients undergoing tympanoplasty only. no of strata: 3. outcomes: 1. improvement of hearing 2. closure of tympanic perforation 3. recurrence of disease 4. external ear canal stenosis tools for measurement of outcomes \[before and after surgery\]: 1. pure tone audiometry 2. impedance audiometry 3. otoendoscopy 4. external ear canal dimensions

Eligibility criteria:
inclusion criteria:chronic tubotympanic otitis media in quiescent phase with intact ossicular chain - exclusion criteria:1. atticoantral otitis media 2. specific otitis media 3. sensorineural hearing loss 4. fixed/dislocated ossicular chain 5. uncorrectable disease focus in nose/throat 6. chronic otitis media in active phase 7. chronic otitis media with complications 8. extensive unresectable tympanosclerosis -

Keywords: otitis media suppurative surgery ear
autologous prp intra ovarian infusion to restore ovarian function in menopausal women

Conditions: Infertility, Female; Anovulatory Infertility; Menopause; Amenorrhea

Summary: autologous prp intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve hormonal profile of women in menopause.

this triple-blind randomized controlled trial (rct) aims to investigate the effectiveness of autologous prp intra ovarian infusion on reactivating ovarian functionality and on promoting folliculogenesis in regard to menopausal women. prp is blood plasma prepared from fresh whole blood that has been enriched with platelets. it is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (vegf), epidermal growth factor (egf), platelet derived growth factor (pdgf), transforming growth factor (tgf) and other cytokines all of which stimulate tissue proliferation and growth. prp has been employed in several medical conditions in orthopedics, dermatology, and ophthalmology for wound healing. it's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated. this study aims to investigate the effect of autologous prp intra ovarian infusion on restoring ovarian tissue functionality in menopausal women.

Eligibility criteria:
inclusion criteria: * age between 45-55 years old * amenorrhea for at least 12 months * discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment. * willing to comply with study requirements exclusion criteria: * any pathological disorder related to reproductive system anatomy * previous poi diagnosis * abnormal karyotype * endometriosis * adenomyosis * fibroids and adhesions * infections in reproductive system * current or previous diagnosis of reproductive system cancer * history of familiar cancer in reproductive system * severe male factor infertility * prior referral for pgt * ovarian inaccessibility * endocrinological disorders (hypothalamus-pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome) * bmi\>30 kg/m2 or bmi\<18.5 kg/m2 * systematic autoimmune disorders

Keywords: ovarian rejuvenation ovarian reactivation; ovulation
tamsulosin to prevent postoperative urinary retention in laparoscopic inguinal hernia repair

Conditions: Post Operative Urinary Retention

Summary: to investigate the effect of tamsulosin on the development of post-operative urinary retention (pur) after elective laparoscopic inguinal hernia repair (lihr). this will be accomplished by administering a pre-operative dose of tamsulosin. the primary outcome is the rate of urinary retention necessitating straight catheterization or insertion of foley catheter prior to discharge.

patients who are scheduled for elective laparoscopic inguinal hernia repair will be consented in the office by the attending physician. an order will be placed during surgery scheduling for tamsulosin with instruction to administer one dose in the preoperative holding area on the day of surgery. the jewish hospital pharmacy will be responsible for providing randomization and placebo medications for double blinding effect. pur will be tracked on the basis of urinary catheterization performed prior to hospital discharge. criteria for catheterization include: i) inability to urinate within 6 hours post-operatively, and bladder scan showing \>400 ml. ii) inability to urinate at any time postoperatively with symptoms of urinary retention (i.e. urgency, bladder discomfort). women of childbearing age will need to have a confirmed negative urine or serum pregnancy test prior to surgery. this will be completed on arrival to the preoperative holding area. to detect the difference between the treated group and control group with a significant alpha (0.5) and power (80%), at least 178 patients will be needed in each group. this was generated using the pearson chi-square test for two proportions. this study will be conducted in the hospital setting at a single institution. patients will be consented for the study in the pre-admission holding area and followed until discharged from the post anesthesia care unit.

Eligibility criteria:
inclusion criteria: 1. all patients undergoing elective laparoscopic inguinal hernia repair, unilateral or bilateral. 2. ≥18 years of age. 3. patients must leave the operating room without at indwelling urinary catheter. exclusion criteria: 1. history of neurogenic bladder requiring routine intermittent catheterization 2. emergent laparoscopic hernia repair. 3. elective laparoscopic hernia repair in conjuncture with an additional operation (e.g. nephrectomy, pelvic surgery) that requires the patient to have a planned, indwelling urinary catheter in the postoperative period. 4. pregnant women.

Keywords: laparoscopic inguinal hernia repair tamsulosin
remote blood pressure management clinical application research

Conditions: Hypertension

Summary: recruit patients with essential hypertension and randomly divide them into three groups. for 24 months, observe the patient's blood pressure level and blood pressure compliance rate,risk assessment, etc.

recruit patients with essential hypertension and randomly divide them into three groups. one group through remote blood pressure management platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders;one group is distributed a set of electronic sphygmomanometers , and the blood pressure is recorded by themselves following routine community hypertension management; one group follows routine community hypertension management. for 24 months, observe the patient's blood pressure level and blood pressure compliance rate,risk assessment, etc. the main technical difficulties and problems to be solved: widely popularize remote blood pressure based on "cloud sharing smart cabinet" management mode. innovation point: provide primary hospitals with an intelligent, simple and efficient innovative tool for the management of residents chronic diseases, and improve the management level of chronic diseases in my country promotly; adopt intelligent terminal equipment to realize automatic data collection and transmission to ensure patient real blood pressure data timely and continuously, providing data reference and basis for academic research and the prevention and treatment of chronic diseases, and promoting scientific research in the prevention and treatment of chronic diseases in my country.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of primary hypertension * must be aged at ≥18 years old and ≤75 years old * must have a smart phone and have the ability to use smart devices * must be local permanent resident population who volunteered to participate in the study and received a 2-year follow-up * must sign informed consent exclusion criteria: * participated in other clinical trials within 4 weeks before the start of this study * the systolic blood pressure in the office was ≥180 mmhg, and/or the diastolic blood pressure was ≥110 mmhg * uremia, creatinine\>250umol/l * history of acute heart disease in the past three months * terminal diseases such as malignant tumors * severe cognitive impairment * severe diabetes patients (glycated hemoglobin\>11%) * severe valvular heart disease, cardiomyopathy, and poor heart function * atrial fibrillation and atrioventricular block * arm circumference \>35cm or \<26cm * spouse or relatives have been included in this research * pregnant or breastfeeding women * live in an unfixed state

Keywords: hypertension; telemedicine; remote blood pressure monitoring
study on the safety and effects on lipids of fm-vp4 in subjects with primary hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to evaluate the safety and effects on lipids of fm-vp4 administered for 12 weeks in subjects with mild to moderate primary hypercholesterolemia.


Eligibility criteria:
inclusion criteria: * mild to moderate primary hypercholesterolemia * able to give informed consent and to comply with study procedures (including diet) exclusion criteria: * homozygous familial hypercholesterolemia * age \ 75 years * pregnant women or women of child-bearing potential
cerebrospinal fluid (csf) drainage study

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: when patients suffer a subarachnoid hemorrhage (bleeding around the brain), they often develop hydrocephalus. this is an enlargement of the fluid-filled spaces (ventricles) in the brain. standard-of-care treatment includes placing an external ventricular drain (evd) to drain off fluid. eventually the evd is weaned with the goal of removing it. occasionally a patient does not tolerate this and a permanent surgery needs to be done to internalize a shunt. though this is done commonly and routinely throughout the world, there are no good studies to address how to optimally set the evd level and how fast to wean it. most set the evd to a level of around 15 mmhg. the investigators hypothesize that setting the evd lower (which will allow higher volume cerebrospinal fluid (csf) drainage through the evd) will improve perfusion at the level of the microcirculation in the brain, and result in improved neurologic outcomes.


Eligibility criteria:
inclusion criteria * age ≥ 18 years * diagnosis of acute subarachnoid hemorrhage (sah), confirmed with noncontrast head ct * sah is suspected to be aneurysmal in source * clinical management requires placement of evd within 2 days of suspected time of hemorrhage exclusion criteria * age \< 18 years * sah of traumatic or non-aneurysmal etiology * patients treated with lumbar drains * evd placement ≥ 3 days after suspected time of hemorrhage * known contraindication to induction of relative intracranial hypotension (e.g. acute subdural hematoma) * pre-morbid mrs ≥ 3 * evd that is suboptimally placed by ct obtained after evd placement (i.e. evd not in the ventricular system)
tdcs and rtms in patients with early disorders of consciousness

Conditions: Disorder of Consciousness; Stroke; Ischemic-hypoxic Encephalopathy

Summary: a randomized controlled study was conducted to explore the efficacy of early transcranial direct current stimulation (tdcs) and repetitive transcranial magnetic stimulation (rtms) to promote wakefulness in patients with disorder of consciousness (doc). in order to improve the prognosis of doc patients with nontraumatic brain injury, we compared the effects of tdcs and rtms on clinical behavior and neurophysiological performance, and selected a wake-up technique that could improve the prognosis of doc patients with nontraumatic brain injury as early as possible, so as to reduce the pain of patients and their loved ones, and to reduce the economic burden of society and families.

to study the efficacy of wakefulness promotion in patients with acute doc due to severe non-traumatic brain injury (including stroke and ischemic-hypoxic encephalopathy), patients with early doc were randomly divided into conventional treatment group, tdcs treatment group and rtms treatment group for 14 consecutive days. clinical scoring, evoked potential assessment, resting-state high-density electroencephalogram(eeg) and tms-eeg assessment with functional analysis of brain network connectivity were applied for multidimensional assessment of brain function before and after wake-up promotion treatment (day 1 and day 15 of enrollment) to explore non-invasive brain stimulation(nibs) techniques that can be performed at the bedside - tdcs, rtms intervention the prognostic follow-up was performed at 3 months, 6 months and 12 months after doc to compare the awakening rate after tdcs and rtms prolongation treatment, and to preferably select an effective prolongation technique for early doc. the safety of tdcs and rtms was also clarified by comparing the differences in adverse effects and complications between tdcs treatment group and rtms treatment group and conventional treatment group.

Eligibility criteria:
inclusion criteria: 1. age 18-80 years 2. diagnosis of stroke or ischemic-hypoxic encephalopathy confirmed by neuroimaging (head mri) 3. doc, glasgow coma score (gcs) \<12 4.2-4 weeks of doc 5.informed consent obtained from the patient's legal representative. exclusion criteria: 1. foreign bodies such as metal or electronic devices in the skull (inside or on the surface of the tissue at the treatment stimulation site) 2. pacemaker or cochlear implants 3. history of epilepsy and family history of epilepsy 4. large cranial defects 5. significant cerebral edema lesions in both dlpfc 6. pregnant women 7. with severe physical diseases such as heart, lung, liver and kidney 8. brain death 9. new intracerebral lesions in patients during the study period affecting the assessment and prognosis, e.g. new stroke

Keywords: transcranial direct current stimulation transcranial magnetic stimulation
clinical study of solo tympanostomy tube device (ttd)

Conditions: Otitis Media; Middle Ear Effusion

Summary: this is a multi-centre, single arm study to evaluate the placement of tympanostomy tubes with the aventamed solo tympanostomy tube device (ttd)


Eligibility criteria:
basic inclusion criteria: * listed for bilateral tympanostomy tube insertion only basic exclusion criteria: * anatomy that precludes sufficient visualisation of both the left and right eardrum with the solo ttd in place. * anatomy that precludes safe access to both the left and right eardrum with the solo ttd * patients in whom a reliable audiogram is not possible

Keywords: tympanostomy tube ventilation tube grommet otitis media middle ear effusion
how much virtual reality intervention improve the balance of patients with cerebral palsy

Conditions: Cerebral Palsy

Summary: the purpose of this clinical study is to investigate how effective virtual reality applications are in adult cerebral palsy rehabilitation. the main questions it aims to answer are: do virtual reality interventions (of becure balance and becure wesense systems) improve balance and is this improvement reflected in the clinic? is there a change in brain functional resting state networks after virtual reality interventions?


Eligibility criteria:
inclusion criteria: being diagnosed with unilateral spastic type cerebral palsy (hemiplegic type) / being between the ages of 18-30 / being able to walk independently (gmfcs i-ii) / not having botox application in the last six months / not using any medication that will affect the study process exclusion criteria: having a history of epileptic attacks / having \>2 spasticity in any joint according to the modified ashworth scale / having severe depression according to the beck depression inventory /having hearing-vision problems

Keywords: adult cerebral palsy functional magnetic reasonance imaging virtual reality becure systems balance resting state functional magnetic reasonance imaging
optimisation of response for organ preservation in rectal cancer : neoadjuvant chemotherapy and radiochemotherapy vs. radiochemotherapy

Conditions: Rectal Cancer

Summary: standard treatment of rectal cancer is rectal excision with neoadjuvant radiochemotherapy. a new concept suggests organ preservation as an alternative to rectal excision in good responders after neoadjuvant radiochemotherapy to decrease surgical morbidity and increase quality of life. the rational is the fact that 15% of patients have sterilized tumours after radiochemotherapy for t3t4 rectal cancer. the french greccar 2 trial is the first phase iii trial investigating this strategy: patients with t2t3 low rectal carcinomas (size ≤4 cm) received 50 gy with capecitabine and good clinical responders (≤2 cm) were randomized between local and rectal excision. the main findings were: the rate of complete pathologic response was higher after radiochemotherapy for small t2t3 than for t3t4 tumours (40% vs 15% ypt0) and good pathologic responders (ypt0-1) were associated with zero positive mesorectal nodes. the objective of the new trial is to increase the proportion of patients treated with organ preservation by optimizing tumour response. as compared to folfiri, tritherapy folfirinox has been shown to enhance the response rate. in patients with colorectal metastases, response rate and r0 resection were twice higher, resulting in improved survival. folfirinox also increases response and chance of r0 resection rates in initially unresectable colorectal metastases, compared to standard or intensified bi-chemotherapy regimens. adding two months of neoadjuvant chemotherapy (folfirinox) before radiochemotherapy, the investigators expect to increase chance of organ preservation rate, as compared to radiochemotherapy alone.


Eligibility criteria:
inclusion criteria: * rectal adenocarcinoma * ct2t3 * cn0-1 (≤ 3 positive lymph nodes or size ≤8mm) * tumour size ≤4 cm * location ≤10 cm from the anal verge * no distant metastasis * patient ≥18 years * ecog ≤2 * effective contraception during the study * patient and doctor have signed informed consent exclusion criteria: * t1 or t4 * tumour size \>4cm * n2 (\>3 positive lymph nodes or size \>8mm) * tumour \> 10 cm from the anal verge * distant metastasis * chronic intestinal inflammation and/or bowel obstruction * contra indication for chemotherapy and/or radiotherapy * previous pelvic radiotherapy or chemotherapy * severe renal, hepatic insufficiency (serum creatinine\<30ml/min) * peripheral neuropathy \> grade 1 * complete or partial dihydropyrimidine deshydrogenase (dpd) deficiency (uracilemia ≥ 16 ng/ml) * concomitant treatment with millepertuis, yellow fever vaccine, phenytoin or sorivudine (or chemically equivalent) * pregnant or breast-feeding woman. * persons deprived of liberty or under guardianship * impossibility for compliance to follow-up

Keywords: organ preservation local excision radiochemotherapy neoadjuvant chemotherapy folfirinox tumour response
oral suction intervention to reduce aspiration and ventilator events: no-aspirate

Conditions: Respiratory Failure

Summary: insertion of a breathing tube to enable treatment with mechanical ventilation (respirator) is often associated with complications, such as infection and lung injury. leakage of secretions around the breathing tube (microaspiration) is a major factor leading to complications. the investigators propose that a standardized, enhanced oral suction protocol will be effective in reducing microaspiration and harms associated with mechanical ventilation. the investigators hypothesize that those randomized to the enhanced oral suction protocol will have less microaspiration and other ventilator-associated conditions than those in the usual care, standard suction group.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * orally intubated with endotracheal tube and treated with mechanical ventilation * 24 hours or less since intubation * expected to be intubated for at least 36 hours after enrollment exclusion criteria: * documented aspiration at time of intubation * intubation to treat known aspiration * treatment with rescue mechanical ventilation therapies (oscillator) * re-intubation * contraindications to receiving the intervention (e.g., oral injuries) * history of lung or head/neck cancers that may produce amylase in the lungs * history of disease that affects saliva production (e.g., sjögren's syndrome) * prisoners

Keywords: mechanical ventilation aspiration suctioning secretions ventilator-associated events